A clinical trail to study the effects of two drugs Iron isomaltoside and Ferric carboxymaltose in patient with Iron Deficiency Anemia.

Iron isomaltoside versus Ferric carboxymaltose in Iron Deficiency Anemia: A randomized clinical trial - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074184

Enrollment

Registered

2024-09-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Inj.Iron isomaltoside IV infusion: Inj.Iron isomaltoside upto 1000 mg IV infusion will be administered (per weekx 2 weeks) Control Intervention1: Inj.Ferric carboxymaltose IV Infusion:

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hemoglobin less than 13g/dL male, and less than 12g/dL female 2. Mean corpuscular volume less than 80 fL 3. Transferrin saturation less than 20% 4. S Ferritin less than 50 ng/mL male, 30 ng/mL for female

Exclusion criteria

Exclusion criteria: 1. Patients receiving other modalities of treatment and/or alternative medicine. 2. Patients who did not consent for the study. 3. Patients with CKD, CLD, malignancy, hemoglobinopathy, and pregnant ladies.

Design outcomes

Primary

Measure	Time frame
Increase in Hemoglobin Timepoint: 06 weeks	—

Secondary

Measure	Time frame
1. Rise in Hemoglobin 2. Reticulocyte response 3. Time required to achieve hemoglobin response. 4. Safety profile Timepoint: 2 weeks & 4 weeks & 06 weeks after initiation of therapy	—

Countries

India

Contacts

Public ContactMaj Dr D Mohanasundharam

COMMAND HOSPITAL (CENTRAL COMMAND) LUCKNOW

mishrak20@gmail.com9871323179

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026